Kathy N Williams
Overview
Explore the profile of Kathy N Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams K, May F, Cummings L, Srivastava N, Shahidi N, Kohansal A, et al.
Gastrointest Endosc
. 2024 Oct;
PMID: 39425707
No abstract available.
2.
Kuhn M, Zhang Y, Favate J, Morita M, Blucher A, Das S, et al.
Am J Physiol Gastrointest Liver Physiol
. 2022 Oct;
323(6):G571-G585.
PMID: 36194131
Colorectal cancer (CRC) is a leading cause of cancer-related death. There is an urgent need for new methods of early CRC detection and monitoring to improve patient outcomes. Extracellular vesicles...
3.
Andres S, Williams K, Plesset J, Headd J, Mizuno R, Chatterji P, et al.
Carcinogenesis
. 2018 Nov;
40(4):569-579.
PMID: 30407516
The RNA-binding protein insulin-like growth factor 2 mRNA binding protein 1 (IMP1) is overexpressed in colorectal cancer (CRC); however, evidence for a direct role for IMP1 in CRC metastasis is...
4.
Andres S, Williams K, Rustgi A
Curr Colorectal Cancer Rep
. 2018 Sep;
14(2):69-79.
PMID: 30237756
Purpose Of Review: Metastatic colorectal cancer (CRC) is a vexing clinical problem. In contrast to early stage disease, once CRC metastasizes to other organs, long-term survival is compromised. We seek...
5.
Tasneen R, Li S, Peloquin C, Taylor D, Williams K, Andries K, et al.
Antimicrob Agents Chemother
. 2011 Sep;
55(12):5485-92.
PMID: 21930883
To truly transform the landscape of tuberculosis treatment, novel regimens containing at least 2 new drugs are needed to simplify the treatment of both drug-susceptible and drug-resistant forms of tuberculosis....
6.
Zhang T, Li S, Williams K, Andries K, Nuermberger E
Am J Respir Crit Care Med
. 2011 Jun;
184(6):732-7.
PMID: 21659613
Rationale: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB) is an emerging global health threat. Proper management of close contacts of infectious patients is increasingly important. However, no evidence-based recommendations for treating...
7.
Ahmad Z, Minkowski A, Peloquin C, Williams K, Mdluli K, Grosset J, et al.
Antimicrob Agents Chemother
. 2011 Feb;
55(4):1781-3.
PMID: 21282421
DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to...
8.
Ahmad Z, Nuermberger E, Tasneen R, Pinn M, Williams K, Peloquin C, et al.
J Antimicrob Chemother
. 2010 Feb;
65(4):729-34.
PMID: 20123722
Objectives: In this study, we sought to compare the sterilizing activity of human-equivalent doses of the 'Denver regimen' against acute tuberculosis (TB) infection in the standard mouse model and in...
9.
Williams K, Brickner S, Stover C, Zhu T, Ogden A, Tasneen R, et al.
Am J Respir Crit Care Med
. 2009 Jun;
180(4):371-6.
PMID: 19520903
Rationale: We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in...
10.
Nuermberger E, Tyagi S, Tasneen R, Williams K, Almeida D, Rosenthal I, et al.
Antimicrob Agents Chemother
. 2008 Feb;
52(4):1522-4.
PMID: 18285479
PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line...